Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

Exclusion criteria

• . Previous systemic chemotherapy or radiation for bladder cancer. Note: Prior immunotherapy or intravesical (administered within the bladder) chemotherapy for superficial disease is acceptable
• . No bladder cancer residual disease, such as patients that are rendered disease free by TURBT
• . History of anaphylactic reaction following exposure to humanized or human therapeutic monoclonal antibodies, hypersensitivity to GM-CSF or yeast derived products, clinically meaningful allergic reactions or any known hypersensitivity or prior reaction to any of the formulation excipients in the study drugs.
• . Known infection with HIV, HBV or HCV.
• . Anticipated use of chemotherapy, radiotherapy, or other immunotherapy not specified in the study protocol while on study
• . Any underlying medical condition that, in the Investigator's opinion, will make the administration of study vaccine hazardous to the patient, would obscure the interpretation of adverse events, or surgical resection. Anticipated use of chemotherapy, radiotherapy, or other immunotherapy not specified in the study protocol while on study
• . Systemic treatment on any investigational clinical trial within 28 days prior to registration.
• . Concurrent treatment with immunosuppressive or immunomodulatory agents, including any systemic steroid (exception: inhaled or topically applied steroids, and acute and chronic standard dose NSAIDs, are permitted). Use of a short course (i.e., ≤ 1 day) of a glucocorticoid is acceptable to prevent a reaction to the IV contrast used for CT scans.